首页>
外国专利>
METHOD OF INCREASING in the body cells of mammals active forms of AMP-activated protein kinase (APMK) METHOD FOR IMPROVING physiological parameters mammals and methods for inducing PROGRAMMABLE death (apoptosis) LIMFOTSIDOV
METHOD OF INCREASING in the body cells of mammals active forms of AMP-activated protein kinase (APMK) METHOD FOR IMPROVING physiological parameters mammals and methods for inducing PROGRAMMABLE death (apoptosis) LIMFOTSIDOV
1.method u043fu043eu0432u044bu0448u0435u043du0438u00a0 u0441u043eu0434u0435u0440u0436u0430u043du0438u00a0 active form in the body u0430u043cu0444 - u0430u043au0442u0438u0432u0438u0440u0443u0435u043cu043eu0439 protein kinase (u0430u043cu043fu043a) by u0432u0432u0435u0434u0435u043du0438u00a0 ingested 5 - u0430u043cu0438u043du043eu0438u043cu0438u0434u0430u0437u043eu043b - 4 - u043au0430u0440u0431u043eu043au0441u0430u043cu0438u0434u0430 (aic), 5 - amino imidazole - 4 - u043au0430u0440u0431u043eu043au0441u0430u043cu0438u0434 - 1 - d - u0440u0438u0431u043eu0444u0443u0440u0430u043du043eu0437u0438u0434u0430 (u0430u0438u043au0430u0440), 5 - u0430u043cu0438u043du043eu0438u043cu0438u0434u0430u0437u043eu043b - 4 - u043au0430u0440u0431u043eu043au0441u0430u043cu0438u0434u0430 - 1 - u0440u0438u0431u043eu0444u0443u0440u0430u043du043eu0437u0438u043b - 5 '- u043cu043eu043du043eu0444u043eu0441u0444u0430u0442u0430 (u0430u0438u043au0430u0440 - s) and / or their metabolic precursors in u043eu0447u0435u0442u0430u043du0438u0438 agentu0437u0430u043cu0435u0434u043bu00a0u044eu0449u0438u043cu0438 or blocking stakes u0430u0438u043au0430u0440 - s in the conversion of inosine 5 '- u043cu043eu043du043eu0444u043eu0441u0444u0430u0442 (iif).;2. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that the active form of u0430u043cu043fu043a u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0444u043eu0441u0444u043eu0440u0438u043bu0438u0440u043eu0432u0430u043du043du0430u00a0 form u0430u043cu043fu043a (u0430u043cu043fu043a - s), in which u0444u043eu0441u0444u043eu0440u0438u043bu0438u0440u043eu0432u0430u043d balance u0442u0440u0435u043eu043du0438u043du0430172 u043au0430u0442u0430u043bu0438u0442u0438u0447u0435u0441u043au043e 1 u0441u0443u0431u044au0435u0434u0438u043du0438u0446u044b.;3. method for p.1, u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0, however, that the agent u0437u0430u043cu0435u0434u043bu00a0u044eu0449u0438u043c or locking the conversion of u0430u0438u043au0430u0440 - s in the iif, u00a0u0432u043bu00a0u0435u0442u0441u00a0 inhibitor u0430u0438u043au0430u0440 u0442u0440u0430u043du0441u0444u043eu0440u043cu0438u043bu0430u0437u044b - iif u0446u0438u043au043bu043eu0433u0438u0434u0440u043eu043bu0430u0437u044b, u0432u044bu0431u0440 u0430u043du043du044bu0439 from group u0430u043du0442u0438u0444u043eu043bu0430u0442u043eu0432, u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of sulfonyl containing u0430u043du0442u0438u0444u043eu043bu0430u0442u043eu0432; u043du0435u0441u0442u0435u0440u043eu0438u0434u043du044bu0445 compounds with anti-inflammatory action, such as sally u0446u0438u043bu043eu0432u0430u00a0 acid, aspirin, ibuprofen, u043du0430u043fu0440u043eu0433u0441u0435u043d, indometacin, sulindac,u0444u043eu043bu0438u0435u0432u0430u00a0 acid, u043cu0435u0444u0435u043du0430u043cu0438u043du043eu0432u0430u00a0 acid; biguanide, methotrexate and its derivatives.;4. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that the agent u0437u0430u043cu0435u0434u043bu00a0u044eu0449u0438u043c or locking the conversion of u0430u0438u043au0430u0440 - s in the iif, u00a0u0432u043bu00a0u0435u0442u0441u00a0 agent, u0441u043du0438u0436u0430u044eu0449u0438u0439 content of 10 - u0444u043eu0440u043cu0438u043bu0442u0435u0442u0440u0430u0433u0438u0434u0440 u043eu0444u043eu043bu0430u0442u0430 (u0444u0442u0433u0444) in the cells of the body.;5. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 p.4, however, that the agent u00a0u0432u043bu00a0u0435u0442u0441u00a0 inhibitor u0434u0438u0433u0438u0434u0440u043eu0444u043eu043bu0430u0442u0440u0435u0434u0443u043au0442u0430u0437u044b (u0434u0433u0444u0440), selected from the group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u043au0430u0442u0435u0445u0438u043du043eu0432 and u043du0435u0441u0442u0435u0440u043eu0438u0434u043du044bu0445 compounds with anti-inflammatory action, such as u0441u0430u043bu0438u0446u0438u043bu043eu0432u0430u00a0 acid, aspirin, sulfasalazine, methotrexate, ibuprofen, naproxen, indomethacin had with u0443u043bu0438u043du0434u0430u043a, u0444u043eu043bu0438u0435u0432u0430u00a0 acid, u043cu0435u0444u0435u043du0430u043cu0438u043du043eu0432u0430u00a0 acid.;6. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that the body of the aic, u0430u0438u043au0430u0440, u0430u0438u043au0430u0440 - s and / or their metabolic precursors and agent, u0437u0430u043cu0435u0434u043bu00a0u044eu0449u0435u0433u043e or locking u043au043eu043du0432u0435u0440 this u0430u0438u043au0430u0440 - s in the iif, u043eu0441u0443u0449u0435u0441u0442u0432u043bu00a0u0435u0442u0441u00a0 oral, intravenous, intramuscular or subcutaneous.;7. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 p.6, however, that the introduction of a heart lung machine, u0430u0438u043au0430u0440, u0430u0438u043au0430u0440 - s and / or their metabolic precursors and agent, u0437u0430u043cu0435u0434u043bu00a0u044eu0449u0435u0433u043e or locking u043au043eu043du0432u0435u0440 this u0430u0438u043au0430u0440 - s in the iif, u043eu0441u0443u0449u0435u0441u0442u0432u043bu00a0u0435u0442u0441u00a0 both simultaneously and in different time sequence.;8. method u0443u043bu0443u0447u0448u0435u043du0438u00a0 physiological parameters of mammal or u043fu043eu0432u044bu0448u0435u043du0438u00a0 its efficiency as a result of u043fu043eu0432u044bu0448u0435u043du0438u00a0 u0441u043eu0434u0435u0440u0436u0430u043du0438u00a0 organism u0430u043au0442u0438u0432u043d oh form u0430u043cu0444 - u0430u043au0442u0438u0432u0438u0440u0443u0435u043cu043eu0439 protein kinase (u0430u043cu043fu043a).;9. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 point 9, so that the body's physiological parameters, u00a0u0432u043bu00a0u044eu0449u0438u043cu0438u0441u00a0 objects u0434u043bu00a0 u0443u043bu0443u0447u0448u0435u043du0438u00a0, u00a0u0432u043bu00a0u044eu0442u0441u00a0 weight, blood pressure, content blood glucose, triglyceride, and lipids.;10. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 p.8, so that workability u043eu043fu0440u0435u0434u0435u043bu00a0u0435u0442u0441u00a0 as u043fu0440u0435u0434u0435u043bu044cu043du0430u00a0 duration or the amount of physical exercise, as well as u0432u0440u0435u043cu00a0 needed the first u0434u043bu00a0 u0432u043eu0441u0441u0442u0430u043du043eu0432u043bu0435u043du0438u00a0 efficiency.;11. method u0438u043du0434u0443u0446u0438u0440u043eu0432u0430u043du0438u00a0 programmed death (apoptosis) of lymphocytes in the blood of patients with u043bu0438u043cu0444u043eu043fu0440u043eu043bu0438u0444u0435u0440u0430u0442u0438u0432u043du044bu043cu0438 u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0u043cu0438 by u043fu043eu0432u044bu0448u0435u043du0438u00a0 u0441u043eu0434u0435u0440u0436u0430u043du0438u00a0 in cages the active form u0430u043cu0444 - u0430u043au0442u0438u0432u0438u0440u0443u0435u043cu043eu0439 protein kinase (u0430u043cu043fu043a).
展开▼